AIM-001 serves as bait for the immune system by triggering inflammation, and trafficking of immune cells to the tumor site. AIM-001 reboots the immune system and increases anti-tumor activity to ripen the tumor for combination treatment with checkpoint inhibitor immunotherapy, and all pillars of cancer therapy – surgery, chemotherapy, tumor targeted therapy, and other immunotherapies.
Aloe Therapeutics is aimed at delivering cancer cures. We have designed a new class of locally delivered immunotherapy, akin to an in situ vaccine, called Allo-Immunotherapy (AIM). AIM is implanted at the tumor site to trigger an influx of immune cells in the tumor microenvironment – turning “cold” , immune deficient tumors into “hot” immune rich tumors, and to turn “hot” tumors “hotter”. AIM will be positioned as a partner of choice for checkpoint immunotherapy combinations to increase increase response rates, extend durability of response, and to expand eligibility for patients with “cold” tumors and limited treatment options. INFLAME WITH AIM
AIM-001 serves as bait for the immune system by triggering inflammation, and trafficking of immune cells to the tumor site. AIM-001 reboots the immune system and increases anti-tumor activity to ripen the tumor for combination treatment with checkpoint inhibitor immunotherapy, and all pillars of cancer therapy – surgery, chemotherapy, tumor targeted therapy, and other immunotherapies.
Stays at the tumor site for sustained impact and allows re-dosing for enhanced immune response.
Fits easily into existing treatment regimens without systemic or overlapping toxicities.
Fits easily into existing treatment regimens without systemic or overlapping toxicities.
Our Trusted Partners are key to our success, collaborating with us to drive innovation and excellence. Together, we share a commitment to delivering outstanding solutions that make a lasting impact.
